Potential genetic markers for prediction of treatment response in Egyptian children infected with HCV genotype 4

Cytokine

Volumn 75, Issue 2, 2015, Pages 349-355

  Rady, Normeen Hany ^a   Darwish, Rania Kamal ^a   Mogahed, Engy Adel ^a   Mandour, Iman Atef ^a   Abo Youssef, Hazem ^a   Sharaf, Sahar Abdel Atty ^a   El Karaksy, Hanaa Mostafa ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Children; HCV; Interleukin 10; Interleukin 28; SNPs

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; GENETIC MARKER; IL10 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERLEUKIN 10; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC HEPATITIS C; DOSE RESPONSE; DRUG TREATMENT FAILURE; EGYPTIAN; FEMALE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C VIRUS; HUMAN; IL 10 GENE; IL 28B GENE; IL 29 GENE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; COMBINATION DRUG THERAPY; DRUG EFFECTS; EGYPT; GENE FREQUENCY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; PRESCHOOL CHILD; TREATMENT OUTCOME; VIRUS LOAD;

HEPATITIS C VIRUS;

ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; EGYPT; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKINS; MALE; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84940614951     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.04.005     Document Type: Article

References (45)

1. Kamal S.M., Nasser I.A. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology 2008, 47:1371-1383.
2. Ministry of Health and Population. Ministry of Health and Population in Egypt. Health Annual Report . [Accessed 30.08.12]. http://www.mohp.gov.eg/Main.asp.
3. Kamal M. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int 2011, 31:45-52.
4. Reis N.R., Motta-Castro A.R., Silva A.M., Teles S.A., Yoshida C.F., Martins R.M. Prevalence of hepatitis C virus infection in quilombo remnant communities in Central Brazil. Rev Inst Med Trop Sao Paulo 2008, 50:359-360.
5. Fukuhara T., Taketomi A., Motomura T., Okano S., Ninomiya A., Abe T., et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010, 139:1577-1585.
6. Grünhage F., Nattermann J. Human genes that limit infection. Best Practice Res Clin Gastroenterol 2010, 24:709-723.
7. Mangia A., Santoro R., Copetti M., Massari M., Piazzolla V., Spada E., et al. Treatment optimization of and prediction of HCV clearance in patients with acute HCV infection. J Hepatol 2013, 59:221-228.
8. Zhang A.M., Maa K., Song Y., Wang B., Feng Y., Liu L., et al. Genetic polymorphisms of the IFNλ genes are associated with biochemical features in Han Chinese with HCV infection from Yunnan Province, China. Infect Genet Evol 2014, 21:161-165.
9. Ge D., Fellay J., Thompson A., Simon J., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
10. Lange C., Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011, 55:692-701.
11. Swiatek B. Is interleukin-10 gene polymorphism a predictive marker in HCV infection?. Cytokine Growth Factor Rev 2012, 23:47-59.
12. Backus L.I., Boothroyd D.B., Phillips B.R., Mole L.A. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007, 46:37-47.
13. Zeuzem S., Diago M., Gane E., Reddy K.R., Pockros P., Prati D., et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004, 127:1724-1732.
14. von Wagner M., Huber M., Berg T., Hinrichsen H., Rasenack J., Heintges T., et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005, 129:522-527.
15. Moreira S., Garcia R.F., Gutberlet A., Bertol B.C., Ferreira L.E., Pinho Mde S., et al. A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome. J Virol Methods 2012, 184:93-97.
16. McCarthy J.J., Li J.H., Thompson A., Suchindran S., Lao X.Q., Patel K., et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010, 138:2307-2314.
17. Montes-Cano M.A., Garcia-Lozano J.R., Abad-Molina C., Romero-Gómez M., Barroso N., Aguilar-Reina J., et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010, 52:33-37.
18. Shi K.Q., Liu W.Y., Lin X.F., Fan Y.C., Chen Y.P., Zheng M.H. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interfero-α plus ribavirin: A meta-analysis. Gene 2012, 507. 27-3.
19. Shaker O, Rashad A, Aziz GA, Raziky ME. Is rs8099917 polymorphism of IL-28B gene a good predictor of response to therapy of HCV than rs12979860? An Egyptian study. Cell Biochem Biophys [Epub ahead of print], [accessed 20.10.14].
20. Wu R.R., Liu F.Q., Zhu S.S., Han J. Association of hepatitis C virus infection and interleukin-28B gene polymorphism in Chinese children. Pak J Med Sci 2014, 30:519-524.
21. Smith K.R., Suppiah V., O'Connor K., Berg T., Weltman M., Abate M.L., et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med 2011, 3:57.
22. Ester A., Parera M., Franco S., Pérez-Alvarez N., Tural C., Clotet B., et al. IL28B SNP rs8099917 is strongly associated with Pegylated Interferon-a and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS ONE 2010, 5:e13771.
23. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345.
24. Oda K., Uto H., Kumagni K., Ido A., Kusumoto K., Shimoda K., et al. Impact of a single nucleotide polymorphism upstream of the IL28B gene in patients positive for anti HCV antibody in an HCV hyperendemic area in Japan. J Med Virol 2014, 86:1877-1885.
25. Rosso C., Abate M.L., Cianco A., Strona S., Caviglia G.P. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients. World J Gastroenterol 2014, 28:13146-13152.
26. Jin G., Kang H., Chen X., Dai D. Evaluation of the relation- ship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population. Infect Genet Evol 2014, 21:214-218.
27. Li W., Zeng Y., Wang J., Zhou B., Zhang J., Zhang H., et al. Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay. Antiviral Res 2012, 94:54-56.
28. Fischer J., Böhm S., Scholz M., Müller T., Witt H., George J., et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012, 55:1700-1710.
29. Guojiang J., Kang H., Chen X., Dai D. Evaluation of the relationship between IL28B, IL10RB and IL28RA single-nucleotide polymorphisms and susceptibility to hepatitis C virus in Chinese Han population. Infect Genet Evol 2014, 21:214-218.
30. Bochud P.Y., Bibert S., Kutalik Z., Patin E., Guergnon J., Nalpas B., et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012, 2:384-394.
31. Thompson A., Muir A., Sulkowski M., Patel K., Tillmann H.L., Clark P.J., et al. Hepatitis C trials that combine investigational agents with pegylated INF should be stratified by interleukin-28B genotype. Hepatology 2010, 52:2243-2244.
32. Marabita F., Aghemo A., De Nicola S., Rumi M.G., Cheroni C., Scavelli R., et al. Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011, 54:1127-1134.
33. Knapp S., Hennig B., Frodsham A., Zhang L., Hellier S., Wright M., et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003, 55:362-369.
34. Abbott W.G., Rigopoulou E., Haigh P., Cooksley H., Mullerova I. Single nucleotide polymorphism in interferon Y and interferon 10 do not influence hepatitis C severity or T-cell reactivity to hepatitis C virus. Liver Int 2004, 24:90-97.
35. Kazunori K., Uto H., Hayashi K., Takahama Y. Interleukin-10 or tumour necrosis factor-α polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 2006, 34:24-31.
36. Chuang J., Yang S., Lu Y., Hsieh Y., Chen C., Chang S.C., et al. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients. Dig Liver Dis 2009, 41:424-430.
37. Sun X.R., Wu J., Shi K.Q., Tang K.F. Relationship between IL-10 gene -1082A/G and -592C/A polymorphisms and the risk of hepatitis C infection: a meta-analysis. J Viral Hepat 2013, 20:602-611.
38. Helal S.F., Gomaa H.E., Thabet E.H., Younan M.A., Helmy N.A. Impact of IL-10 (-1082) promoter-single nucleotide polymorphism on the outcome of hepatitis C virus genotype 4 infection. Clin Med Insights Gastroenterol 2014, 7:19-24.
39. Asselah T., De Muynck S., Broet P., Masliah-Planchon J., Blanluet M., Bièche I., et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2011, 3:527-532.
40. Gewaltig J., Mangasser-Stephan K., Gartung C., Biesterfeld S., Gressner A.M. Association of polymorphisms of the transforming growth factor-1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta 2002, 316:83-94.
41. Manue R., Eslam M., Ruiz A., Maraver M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int 2011, 31:443-460.
42. Howell C.D., Gorden A., Ryan K.A., Thompson A.J., Ibrahim C., Fried M., et al. Single nucleotide polymorphism upstream of interleukin 28B associated with phase 1 and phase 2 of early viral kinetics in patients infected with HCV genotype 1. J Hepatol 2012, 56:557-563.
43. Domagalski K., Pawłowska M., Tretyn A., Halota W., Pilarczyk M., Smukalska E., et al. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis 2013, 3:745-754.
44. Lawitz E., Mangia A., Wyles D., Rodriguez-Torres M., Hassanein T., Gordon S.C., et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
45. Hézode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 2014 Jul 30. pii: gutjnl-2014-307498 . [Epub ahead of print]. doi:10.1136/gutjnl-2014-307498.